Natus Medical (NASDAQ:NTUS) Updates Q4 2021 Earnings Guidance

Natus Medical (NASDAQ:NTUS) issued an update on its fourth quarter 2021 earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.410-$0.460 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.400. The company issued revenue guidance of $124 million-$128 million, compared to the consensus revenue estimate of $123.50 million.Natus Medical also updated its FY 2021 guidance to $1.130-$1.180 EPS.

Shares of NASDAQ NTUS traded down $0.14 during trading on Thursday, hitting $25.17. The company had a trading volume of 62,562 shares, compared to its average volume of 154,699. The company has a market cap of $859.61 million, a P/E ratio of 52.44 and a beta of 0.52. Natus Medical has a 52 week low of $19.03 and a 52 week high of $29.70. The business’s 50-day moving average is $25.43 and its 200 day moving average is $26.09.

Natus Medical (NASDAQ:NTUS) last posted its quarterly earnings results on Thursday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.30 by ($0.02). Natus Medical had a net margin of 3.59% and a return on equity of 9.07%. During the same period in the prior year, the firm posted $0.09 earnings per share. As a group, equities research analysts expect that Natus Medical will post 1.15 earnings per share for the current fiscal year.

Separately, Zacks Investment Research downgraded shares of Natus Medical from a hold rating to a sell rating in a research note on Wednesday, November 10th.

A number of large investors have recently made changes to their positions in the business. Royal Bank of Canada raised its stake in Natus Medical by 50.7% during the 3rd quarter. Royal Bank of Canada now owns 4,296 shares of the company’s stock valued at $108,000 after purchasing an additional 1,445 shares during the period. LPL Financial LLC increased its stake in shares of Natus Medical by 32.1% in the third quarter. LPL Financial LLC now owns 12,230 shares of the company’s stock worth $307,000 after acquiring an additional 2,970 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Natus Medical by 2.0% in the third quarter. Bank of New York Mellon Corp now owns 320,947 shares of the company’s stock worth $8,049,000 after acquiring an additional 6,281 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Natus Medical by 61.7% in the third quarter. UBS Group AG now owns 60,263 shares of the company’s stock worth $1,512,000 after acquiring an additional 23,005 shares during the last quarter. 91.20% of the stock is currently owned by institutional investors.

About Natus Medical

Natus Medical, Inc provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Featured Story: What is a SEC Filing?

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.